Japan and China said Friday they have reached a deal toward resolving their disputes over the discharge of treated ...

The NHS England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML).

Today’s positive decision follows the manufacturer, Daiichi Sankyo, offering a fair price for the treatment that the National Institute for Health and Care Excellence (NICE) determined to be ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

This journal utilises an Online Peer Review Service (OPRS) for submissions. By clicking "Continue" you will be taken to our partner site https://mc.manuscriptcentral ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...

DelveInsight's CEACAM5 Drugs Market Insights report includes a comprehensive understanding of current treatment practices, ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

As a result, commercial teams are evolving as valuable partners to HCPs. From educating key experts before launch and ...

GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape. The most common ...

at the 2024 European Society for Medical Oncology (#ESMO24). DS-9606 is an investigational CLDN6 directed, modified pyrrolobenzodiazepine (PBD) antibody drug conjugate (ADC) from Daiichi Sankyo's (TSE ...